Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
TAKEDA VACCINES
Takeda's Dengue Vaccine Manufacturing Plant, Singen, Germany
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
ABOUT DENGUE AND TAKEDA'S DENGUE VACCINE CANDIDATE (TAK-003)
wave1presentation Foreign Issuer Report 6-K
TAK-003 - News, Articles etc. - European Pharmaceutical Review
Takeda's dengue vaccine prevents hospitalisations in TIDES trial
CONTRIBUTING TO THE FIGHT AGAINST DENGUE
Global First Approval For Takeda's Dengue Vaccine, In Indonesia :: Scrip
TAK-003
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
gemirdaypresentation
Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech
VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
TAK-003 induces functional DENV cross-reactive cellular immmunity | Immunopaedia
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
FDA grants priority review to Takeda's dengue vaccine – PharmaLive
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today
Takeda's dengue vaccine TAK-003 shows efficacy through 4.5 years in trial | Seeking Alpha
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram
